Full Professor(heuristic)

Colorectal Cancer Treatments and Studies · Oncology

Compare more Oncology professors.

h-index53
i10-index126
Publications536
Citations30,857

Grants

6 total · 3 active

NIH #R01CA296410

Optimization of an active mutant KRAS peptide vaccine in colorectal cancer

Active
Amount
$500K–$600K
Period
2025-01-10 → 2029-12-31
PIs
2

Awarded at JOHNS HOPKINS UNIVERSITY

NIH #P01CA247886

Mechanisms of immunomodulation with epigenetic therapy

Active
Amount
$300K–$400K
Period
2021-06-01 → 2027-05-31
PIs
1

Awarded at JOHNS HOPKINS UNIVERSITY

NIH #P30CA006973

Cancer Genetics and Epigenetics

Active
Amount
$300K–$400K
Period
1997-05-07 → 2027-05-31
PIs
1

Awarded at JOHNS HOPKINS UNIVERSITY

Active grants are a starting point, not proof of an opening. Confirm recruiting and funding with the professor, current students, and your written offer. Learn how to verify PhD funding →

All Grants

6 total · 3 active

NIH #R01CA296410

Optimization of an active mutant KRAS peptide vaccine in colorectal cancer

Active
Amount
$500K–$600K
Period
2025-01-10 → 2029-12-31
PIs
2

Awarded at JOHNS HOPKINS UNIVERSITY

NIH #P01CA247886

Mechanisms of immunomodulation with epigenetic therapy

Active
Amount
$300K–$400K
Period
2021-06-01 → 2027-05-31
PIs
1

Awarded at JOHNS HOPKINS UNIVERSITY

NIH #P30CA006973

Cancer Genetics and Epigenetics

Active
Amount
$300K–$400K
Period
1997-05-07 → 2027-05-31
PIs
1

Awarded at JOHNS HOPKINS UNIVERSITY

NIH #T32CA009071

Molecular Targets for Cancer Detection and Treatment

Amount
$600K–$700K
Period
1979-09-15 → 2022-06-30
PIs
2

Awarded at JOHNS HOPKINS UNIVERSITY

NIH #R01CA228414

Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinoma

Amount
$400K–$500K
Period
2018-07-03 → 2022-06-30
PIs
2

Awarded at EMORY UNIVERSITY

NIH #R21CA172997

Targeting RAS signaling with CDK and AKT inhibition in pancreatic cancer

Amount
$200K–$300K
Period
2013-07-01 → 2015-06-30
PIs
1

Awarded at JOHNS HOPKINS UNIVERSITY

Recent Public Signals

  1. New paper: A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer (Clinical Cancer Research)2026-06-30
  2. New NIH award: Optimization of an active mutant KRAS peptide vaccine in colorectal cancer2025-01-10
  3. New NIH award: Mechanisms of immunomodulation with epigenetic therapy2021-06-01

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

Data Freshness

  • Publications as of 2026-07-09
  • Grants as of 2026-09-03

Data may not be current

Find elsewhere

Institution / lab homepage Search on ResearchGate

ORCID: 0000-0002-9613-3988

Professor Insights

Career Trajectory